{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:07:26Z","timestamp":1776265646640,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009888","name":"Regione Toscana","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009888","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007378","name":"Associazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007378","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.expneurol.2019.113065","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T10:57:52Z","timestamp":1568631472000},"page":"113065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Neuroimmunological characterization of a mouse model of primary progressive experimental autoimmune encephalomyelitis and effects of immunosuppressive or neuroprotective strategies on disease evolution"],"prefix":"10.1016","volume":"322","author":[{"given":"Daniela","family":"Buonvicino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Ranieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pratesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Guasti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Chiarugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2019.113065_bb0005","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1007\/s12035-018-1368-2","article-title":"Bezafibrate upregulates mitochondrial biogenesis and influence neural differentiation of human-induced pluripotent stem cells","volume":"56","author":"Augustyniak","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0010","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s40265-018-0984-5","article-title":"Therapeutic advances and challenges in the treatment of progressive multiple sclerosis","volume":"78","author":"Baldassari","year":"2018","journal-title":"Drugs."},{"key":"10.1016\/j.expneurol.2019.113065_bb0015","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1172\/JCI33464","article-title":"Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis","volume":"118","author":"Basso","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.expneurol.2019.113065_bb0020","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.msard.2017.09.030","article-title":"High dose biotin as treatment for progressive multiple sclerosis","volume":"18","author":"Birnbaum","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.expneurol.2019.113065_bb0025","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/1531-8249(200012)48:6<893::AID-ANA10>3.0.CO;2-B","article-title":"Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients","volume":"48","author":"Bjartmar","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0030","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0022-510X(02)00069-2","article-title":"Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease","volume":"206","author":"Bjartmar","year":"2003","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.expneurol.2019.113065_bb0035","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12031-008-9115-1","article-title":"Variations in mitochondrial DNA copy numbers in MS brains","volume":"35","author":"Blokhin","year":"2008","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.expneurol.2019.113065_bb0040","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.chembiol.2018.01.012","article-title":"Identification of the nicotinamide salvage pathway as a new toxification route for antimetabolites","volume":"25","author":"Buonvicino","year":"2018","journal-title":"Cell. Chem. Biol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0045","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028985","article-title":"Neurodegeneration in progressive multiple sclerosis","volume":"8","author":"Campbell","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.expneurol.2019.113065_bb0050","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/ana.22109","article-title":"Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis","volume":"69","author":"Campbell","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0055","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1177\/1352458511399113","article-title":"PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity","volume":"17","author":"Cavone","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.expneurol.2019.113065_bb0060","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/bph.12525","article-title":"Long-term suppression of EAE relapses by pharmacological impairment of epitope spreading","volume":"171","author":"Cavone","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0065","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbi.2015.06.019","article-title":"Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound","volume":"50","author":"Cavone","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.expneurol.2019.113065_bb0070","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1046\/j.1471-4159.2003.01684.x","article-title":"Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders","volume":"85","author":"Chiarugi","year":"2003","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2019.113065_bb0075","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11940-018-0496-3","article-title":"Disease-modifying treatment in progressive multiple sclerosis","volume":"20","author":"Ciotti","year":"2018","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0080","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/7854_2015_378","article-title":"Modelling MS: Chronic-Relapsing EAE in the NOD\/Lt mouse strain","volume":"26","author":"Dang","year":"2015","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.expneurol.2019.113065_bb0085","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-3083.2010.02451.x","article-title":"Specific and strain-independent effects of dexamethasone in the prevention and treatment of experimental autoimmune encephalomyelitis in rodents","volume":"72","author":"Donia","year":"2010","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0090","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ana.20736","article-title":"Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients","volume":"59","author":"Dutta","year":"2006","journal-title":"Ann.Neurol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0095","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/ni.1775","article-title":"Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE","volume":"10","author":"Farez","year":"2009","journal-title":"Nat.Immunol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.neuropharm.2017.01.039","article-title":"Post onset, oral rapamycin treatment delays development of mitochondrial encephalopathy only at supramaximal doses","volume":"117","author":"Felici","year":"2017","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.expneurol.2019.113065_bb0105","doi-asserted-by":"crossref","first-page":"10593","DOI":"10.1074\/jbc.M110.162867","article-title":"Phenotypic changes, signaling pathway, and functional correlates of GPR17-expressing neural precursor cells during oligodendrocyte differentiation","volume":"286","author":"Fumagalli","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2019.113065_bb0110","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.neuropharm.2005.09.005","article-title":"Blockade of intracellular calcium release induces an antidepressant-like effect in the mouse forced swimming test","volume":"50","author":"Galeotti","year":"2006","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.expneurol.2019.113065_bb0115","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1093\/intimm\/dxl080","article-title":"A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses","volume":"18","author":"Huntington","year":"2006","journal-title":"Int. Immunol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0165-5728(99)00153-8","article-title":"Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing--remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide","volume":"102","author":"Ichikawa","year":"2000","journal-title":"J. Neuroimmunol."},{"issue":"1\u201312","key":"10.1016\/j.expneurol.2019.113065_bb0125","article-title":"The epigenetic drug Trichostatin a ameliorates experimental autoimmune encephalomyelitis via T cell tolerance induction and impaired influx of T cells into the spinal cord","volume":"108","author":"Jayaraman","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2019.113065_bb0130","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.expneurol.2019.113065_bb0135","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/bph.12413","article-title":"Turn up the power - pharmacological activation of mitochondrial biogenesis in mouse models","volume":"171","author":"Komen","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0140","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.3389\/fimmu.2018.03116","article-title":"Pathogenic mechanisms associated with different clinical courses of multiple sclerosis","volume":"9","author":"Lassmann","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0145","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-016-1631-4","article-title":"Multiple sclerosis: experimental models and reality","volume":"133","author":"Lassmann","year":"2017","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0150","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40478-014-0097-7","article-title":"Axonal degeneration in multiple sclerosis: can we predict and prevent permanent disability?","volume":"2","author":"Lee","year":"2014","journal-title":"Acta Neuropathol. Commun."},{"key":"10.1016\/j.expneurol.2019.113065_bb0155","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/08916934.2011.616558","article-title":"Unique B cell responses in B cell-dependent and B cell-independent EAE","volume":"45","author":"Liu","year":"2012","journal-title":"Autoimmunity."},{"key":"10.1016\/j.expneurol.2019.113065_bb0160","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0166-2236(00)01746-X","article-title":"The link between excitotoxic oligodendroglial death and demyelinating diseases","volume":"24","author":"Matute","year":"2001","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.expneurol.2019.113065_bb0165","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/brain\/aww113","article-title":"IL-10-dependent Tr1 cells attenuate astrocyte activation and ameliorate chronic central nervous system inflammation","volume":"139","author":"Mayo","year":"2016","journal-title":"Brain."},{"key":"10.1016\/j.expneurol.2019.113065_bb0170","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nm1202","article-title":"Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis","volume":"11","author":"McMahon","year":"2005","journal-title":"Nat.Med."},{"key":"10.1016\/j.expneurol.2019.113065_bb0175","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jnnp.50.5.511","article-title":"A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects","volume":"50","author":"Milligan","year":"1987","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.expneurol.2019.113065_bb0180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2019.113065_bb0185","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.mito.2012.12.003","article-title":"Bezafibrate improves mitochondrial function in the CNS of a mouse model of mitochondrial encephalopathy","volume":"13","author":"Noe","year":"2013","journal-title":"Mitochondrion."},{"key":"10.1016\/j.expneurol.2019.113065_bb0190","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ymgme.2015.08.009","article-title":"Biotin deprivation impairs mitochondrial structure and function and has implications for inherited metabolic disorders","volume":"116","author":"Ochoa-Ruiz","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2019.113065_bb0195","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/WCO.0000000000000195","article-title":"Progressive multiple sclerosis","volume":"28","author":"Ontaneda","year":"2015","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0200","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jsb.2010.06.017","article-title":"Mitochondrial configurations in peripheral nerve suggest differential ATP production","volume":"173","author":"Perkins","year":"2011","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0205","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/ana.1123","article-title":"Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions","volume":"50","author":"Peterson","year":"2001","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/71555","article-title":"Glutamate excititoxicity in a model of multiple sclerosis","volume":"6","author":"Pitt","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.expneurol.2019.113065_bb0215","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1212\/WNL.0000000000001066","article-title":"Epitope spreading as an early pathogenic event in pediatric multiple sclerosis","volume":"83","author":"Quintana","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.expneurol.2019.113065_bb0220","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2174\/1389557516666160923132611","article-title":"Pharmacological effects of biotin in animals","volume":"17","author":"Riveron-Negrete","year":"2017","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.expneurol.2019.113065_bb0225","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2337\/diab.39.5.583","article-title":"Prevention of type I diabetes in NOD mice by adjuvant immunotherapy","volume":"39","author":"Sadelain","year":"1990","journal-title":"Diabetes."},{"key":"10.1016\/j.expneurol.2019.113065_bb0230","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.neuropharm.2015.08.028","article-title":"Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis","volume":"110","author":"Sedel","year":"2016","journal-title":"Neuropharmacology."},{"key":"10.1016\/j.expneurol.2019.113065_bb0235","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00018-012-1096-0","article-title":"Structure and function of biotin-dependent carboxylases","volume":"70","author":"Tong","year":"2013","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.expneurol.2019.113065_bb0240","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40263-018-0528-2","article-title":"MD1003 (high-dose pharmaceutical-grade biotin) for the treatment of chronic visual loss related to optic neuritis in multiple sclerosis: a randomized, double-blind, placebo-controlled study","volume":"32","author":"Tourbah","year":"2018","journal-title":"CNS.Drugs."},{"key":"10.1016\/j.expneurol.2019.113065_bb0245","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1474-4422(09)70043-2","article-title":"Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis","volume":"8","author":"Trapp","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0250","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis","volume":"338","author":"Trapp","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.expneurol.2019.113065_bb0255","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1097\/01.jnen.0000190067.20935.42","article-title":"Grey matter pathology in multiple sclerosis","volume":"64","author":"Vercellino","year":"2005","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0260","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1038\/s41598-017-02576-5","article-title":"Simvastatin and Bezafibrate ameliorate emotional disorder induced by high fat diet in C57BL\/6 mice","volume":"7","author":"Wang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.expneurol.2019.113065_bb0265","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1212\/01.wnl.0000237551.26858.39","article-title":"Neocortical neuronal, synaptic, and glial loss in multiple sclerosis","volume":"67","author":"Wegner","year":"2006","journal-title":"Neurology."},{"key":"10.1016\/j.expneurol.2019.113065_bb0270","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.4049\/jimmunol.166.4.2831","article-title":"Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; nonimmunized nonobese diabetic mice can develop autoimmune encephalitis","volume":"166","author":"Winer","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0275","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molmed.2013.11.007","article-title":"Mitochondrial dysfunction contributes to neurodegeneration in multiple sclerosis","volume":"20","author":"Witte","year":"2013","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.expneurol.2019.113065_bb0280","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00401-012-1052-y","article-title":"Reduced expression of PGC-1alpha partly underlies mitochondrial changes and correlates with neuronal loss in multiple sclerosis cortex","volume":"125","author":"Witte","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.expneurol.2019.113065_bb0285","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.neuron.2018.12.023","article-title":"Calcium influx through plasma-membrane nanoruptures drives axon degeneration in a model of multiple sclerosis","volume":"101","author":"Witte","year":"2019","journal-title":"Neuron."},{"key":"10.1016\/j.expneurol.2019.113065_bb0290","doi-asserted-by":"crossref","first-page":"8434","DOI":"10.4049\/jimmunol.180.12.8434","article-title":"Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis","volume":"180","author":"W\u00fcst","year":"2008","journal-title":"J. Immunol."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488619302146?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488619302146?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T05:54:34Z","timestamp":1758002074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488619302146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":58,"alternative-id":["S0014488619302146"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2019.113065","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neuroimmunological characterization of a mouse model of primary progressive experimental autoimmune encephalomyelitis and effects of immunosuppressive or neuroprotective strategies on disease evolution","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2019.113065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113065"}}